• About Nektar
  • Our Leadership
  • Corporate Giving
  • Locations
  • Contacts
• Pipeline
  • Pipeline Overview
  • Nektar Proprietary Products
  • Nektar Partnered Products
  • Drug Development Platforms
• Partners
  • Nektar Partners
• Investor Relations
  • Press Releases
  • Stock Information
  • Financial Events Calendar
  • Analyst Coverage
  • Annual and Financial Reports
  • Corporate Governance
  • Investor Contacts
  • FAQ
  • Investor Advisory
• Media Room
  • Lead Product Backgrounder
  • Press Releases
  • Press Kit
  • Media Contacts
• Information Center
  • Scientific & Partnering Events
  • Multimedia
  • Library
  • Email Alerts
• Careers
  • Life at Nektar
  • Career Opportunities
  • Recruitment Calendar
  • Summer Internships
  • Benefits
  • Recruiting Information
  • Nektar Employee Foundation

• Lead Product Backgrounder
• Press Releases
• Press Kit
  • History of Nektar
  • Nektar Leadership
  • Nektar Product Portfolio
• Media Contacts

The company was founded as Inhale Therapeutic Systems, Inc. by John S. Patton in 1990 and changed its name to Nektar Therapeutics in 2003. Nektar is headquartered in San Carlos, California, with additional locations in Huntsville, Alabama,India, and Ireland. Our scientists developed the first pulmonary delivery system for macromolecule therapeutics, creating new opportunities to potentially offer patients a non-invasive alternative to injections. This innovative, breakthrough system is used in the company's flagship partnered product, Exubera® (insulin human [rDNA origin]) Inhalation Powder, which has been approved in the U.S., EU, Brazil and Mexico for the treatment of type 1 and type 2 diabetes patients. Specializing in both formulation and device development, the company has a broad pulmonary technology portfolio that also includes delivery solutions to treat the local lung for infections as well as to deliver medicines for fast-onset treatment of pain.

The company is also a market leader in PEG-based drug delivery and development, and has enabled blockbuster drugs for its partners such as Roche's PEGASYS® and Amgen's Neulasta.